| Aggregate Evidence Quality . | Grade B (Aggregate Level of Evidence Equals B, Given 3 Studies With Similar Findings) . |
|---|---|
| Benefits | Early detection of HTN |
| Risks, harm, cost | Additional costs related to the placement of ABPM |
| Benefit–harm assessment | Benefits exceed harms |
| Intentional vagueness | Frequency of measurement. Because the development of HTN after coarctation repair is influenced by many factors, the ideal onset of screening for HTN (including MH) is unknown |
| Role of patient preferences | None |
| Exclusions | Individuals with a history of residual aortic arch obstruction |
| Strength | Strong recommendation |
| Key references | 58,112,113 |
| Aggregate Evidence Quality . | Grade B (Aggregate Level of Evidence Equals B, Given 3 Studies With Similar Findings) . |
|---|---|
| Benefits | Early detection of HTN |
| Risks, harm, cost | Additional costs related to the placement of ABPM |
| Benefit–harm assessment | Benefits exceed harms |
| Intentional vagueness | Frequency of measurement. Because the development of HTN after coarctation repair is influenced by many factors, the ideal onset of screening for HTN (including MH) is unknown |
| Role of patient preferences | None |
| Exclusions | Individuals with a history of residual aortic arch obstruction |
| Strength | Strong recommendation |
| Key references | 58,112,113 |